Radiofrequency ablation

The Danish Health Data Authority quarterly updates the Health Care Classification System (SKS). The latest version was published in mid-June 2025 to come into force on July 1, 2025. Among other changes, seventy-eight new procedure codes were introduced concerning dermatology, endoscopy, ENT, interventional radiology, obstetrics and gynecology, orthopedics, spine, surgical procedures, and some other fields.

On April 8, 2025, the National Union of Health Insurance Funds issued an update to the Common Classification of Medical Procedures (CCAM), which serves as a reimbursement nomenclature for medical procedures in hospital and ambulatory settings. Changes include the introduction of new procedure codes, provisional registration of several procedure codes, and modification of existing services. Newly introduced procedure codes concern cardiovascular and peripheral vascular procedures, interventional radiology, ENT, and others. The update takes effect on July 1, 2025.

In November 2024, the National Institute for Health and Care Excellence (NICE) published one new Interventional Procedures Guidance concerning endoscopic bipolar radiofrequency ablation for malignant biliary obstruction. Furthermore, one new clinical guideline was published, and two were updated.

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in July 2024. Nine recommendations were published concerning the registration of medical devices in the List of Reimbursable Products and Services (LPPR). Opinions concern cardiovascular, neurovascular, interventional radiology, nephrology and urology, orthopedic, endocrine devices, and in-vitro diagnostic tests, as well as medical aids.

In July 2024, the National Institute for Health and Disability Insurance (INAMI-RIZIV) approved a new agreement (Convention) allowing reimbursement for percutaneous CT-guided ablation of renal, hepatic, pulmonary, and bone tumors. The agreement will come into force on November 1, 2024, and will be valid until October 31, 2029.

In June 2024, the Finnish Coordinating Center for Health Technology Assessment announced that two rapid hospital assessments in the extracorporeal treatments and endoscopy fields and one Digi-HTA were accomplished.

In December 2023, the National Institute for Health and Care Research (NIHR) in England released two MedTech-related assessments in its Health Technology Assessment (HTA) Journal, which concerned ablative and non-surgical therapies for hepatocellular carcinoma and hidradenitis suppurativa treatment. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs National Institute for Health and Care Excellence (NICE) guidance.

On December 1, 2023, the Belgian National Institute for Health and Disability Insurance (INAMI/RIZIV) updated several articles of the Nomenclature. New procedure codes with reimbursement fees and associated conditions concerning cardiovascular, neurology, and obstetrics fields were added.

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in November 2023. Seven recommendations were published in relation to the registration of medical devices in the List of reimbursable products and services (LPPR). Opinions concern cardiovascular, nephrology and urology, and orthopedic devices, as well as medical aids.

The HTA body of the Tuscany Regional Healthcare issues three types of documents: full HTA reports, rapid HTA reports, and motivational forms. With regional decree 24192 of November 15, 2023, Tuscany Regional Healthcare published one assessment and one re-assessment of medical devices in the cardiovascular and men's health areas.

In June 2023, the National Institute for Health and Care Excellence (NICE) published five new Interventional Procedure Guidance (intraoperative electron beam radiotherapy, minimally invasive fusionless posterior-approach surgery to correct idiopathic scoliosis, endoscopic ultrasound-guided gallbladder drainage, radiofrequency denervation for osteoarthritic knee pain, and Botulinum toxin type A injections into the urethral sphincter), two new Diagnostic Guidance (transperineal biopsy for prostate cancer, and FibroScan for liver fibrosis and cirrhosis), and two Medtech Innovation Briefings (MiraQ cardiac TTFM, Proov Confirm; their development started before April 2023). Also, four clinical guidelines were updated.

In May 2023, the National Institute for Health and Care Research (NIHR) in England released two MedTech-related reports in its Health Technology Assessment (HTA) Journal, which endoscopic radiofrequency ablation in malignant biliary obstruction and screening for ovarian cancer. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs National Institute for Health and Care Excellence (NICE) guidance.